Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis discusses appointment of Jonathan Symonds

Novartis discusses appointment of Jonathan Symonds

13th May 2009

Novartis has stated Jonathan Symonds is well suited to take on the role of chief financial officer (CFO) at the company.

He currently works at Goldman Sachs as the managing director of investment banking. Previous roles include KPMG partner, Zeneca’s finance director and chief financial officer at AstraZeneca.

Mr Symonds will join Novartis on September 1st and will report to Raymund Breu, who is due to retire on March 31st 2010 after 35 years with the firm.

“Jonathan Symonds’ financial expertise, broad industry experience and deep knowledge of the healthcare industry make him especially suited to take on the responsibilities of CFO of Novartis from Raymund Breu,” remarked chairman and chief executive officer of the company Dr Daniel Vasella.

Earlier this month, the European Commission approved Novartis’ Glivec to become the first treatment across the continent to reduce the risk of relapse in adults who have undergone surgery to remove gastrointestinal stromal tumours.

As well as applying to all 27 EU member states, the decision is also valid in Iceland and Norway. There have been furhter authorisations of the treatment in Switzerland, the US and other countries.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.